Fig. 1: HNSCC cell lines and patient samples express SLC2A1 (GLUT1). | Cell Death Discovery

Fig. 1: HNSCC cell lines and patient samples express SLC2A1 (GLUT1).

From: GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells

Fig. 1

mRNA expression of several SLC2A transporters in HNSCC cell lines A SCC47, B RPMI2650, C FaDu, and D SCC90 measured using qPCR relative to housekeeping UBC (mean ± SD, n = 3, separate passages of each cell type). E SLC2A family expression in 62 total HNSCC immortalized cell lines downloaded from Cancer Dependency Map (depmap) Project (Broad Institute). mRNA expression of several SLC2A transporters in HNSCC F tumor and G normal tissue relative to UBC (mean ± SD with n = 6 patients). H Matched expression of SLC2A1 between HNSCC patient tumors and normal tissue relative to UBC (mean ± SD; n = 6 patients). No significant difference by paired t-test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), and no statistical significance (ns or no indication). I Boxplot of SLC2A1 expression in HNSCC tumor samples (n = 519) and normal tissue samples (n = 44), generated using GEPIA2. P < 0.05 (*). J Plots of SCL2A1 expression showing no marked changes with cancer stage (bottom), generated using GEPAI2. K Heatmap of SLC2A1 expression across multiple cancer types from GEPIA2, showing a pattern of SLC2A1 being the highest expressed or among the highest expressed SLC2A isoforms across cancer types. L Diagram of internal regions with highest upregulation of SLC2A1 in tumor tissue (regardless of cancer sub-type). Adapted from GEPIA2 Interactive Bodymap. TCGA cancer abbreviations: ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL cholangio carcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, ESCA esophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma, UVM uveal melanoma.

Back to article page